ArticleBMJ open2021

Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.

Shuhang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.